Tau protein is best known for what happens when it goes wrong. In Alzheimer’s disease and related tauopathies, Tau forms neurofibrillary tangles, disrupts cellular transport, and is implicated in mitochondrial dysfunction, a hallmark of neurodegeneration. This pathological picture is so dominant that the protein’s normal, day-to-day function is often reduced to a single line: it stabilizes microtubules.
A new study published in PNAS suggests this view is incomplete. Tau, it turns out, has a second, previously underappreciated physiological role: it acts as a brake on mitochondrial fusion.
The study, led by Dr. Konstantinos Palikaras at the University of Crete and an international team of 19 authors, demonstrates that loss of Tau, or its evolutionary counterpart in roundworms, PTL-1, triggers a pro-fusion state in mitochondria. The resulting mitochondrial elongation and hyperconnectivity are accompanied by increased oxygen consumption, elevated stress resistance, and, under certain conditions, extended survival.
The mechanism is conserved from nematodes to mammals, and it operates through a specific molecular pathway centered on mitofusins, the GTPase proteins that drive the fusion of mitochondrial outer membranes.
Tau as a Brake, Not Just a Scaffold
The researchers generated Tau-knockout mice and compared their brain mitochondria to wild-type controls. The knockout mitochondria were more fused, more elongated, and more interconnected. Biochemically, the team observed reduced levels of the fission protein Drp1 in the mitochondrial fraction and increased levels of the fusion proteins Mfn1 and Mfn2, the mammalian mitofusins.
In isolated brain mitochondria from the knockout mice, basal and ADP-stimulated oxygen consumption rates were elevated, as was ATP-linked respiration. Proton leak increased. In primary cortical neurons from the knockout animals, mitophagy (the targeted recycling of damaged mitochondria) was also elevated.
Crucially, the same pattern held in Caenorhabditis elegans. Worms lacking ptl-1, the sole nematode homolog of Tau, showed the same mitochondrial fusion phenotype, indicating the regulatory function is evolutionarily ancient.
Epistasis Narrows the Mechanism
To determine how Tau/PTL-1 restrains fusion, the team turned to C. elegans genetics. They crossed ptl-1 knockout worms with worms lacking fzo-1, the nematode homolog of mitofusins. The double knockout, missing both the brake and the fusion engine, looked essentially wild-type. All the hallmark phenotypes of ptl-1 loss, mitochondrial fusion, stress resistance, longevity under mild heat, were abolished.
Conversely, overexpressing fzo-1 in an otherwise wild-type worm reproduced the effects of ptl-1 loss: increased fusion, elevated stress resistance, and extended survival.
This epistasis places Tau and mitofusins in the same genetic pathway. The model that emerges is straightforward: wild-type Tau normally restrains mitofusin-mediated fusion. Remove Tau, and the brake is released.
Stress Resistance With a Trade-Off
With fusion unrestrained, mice and worms became more resilient to certain stressors. Worms lacking ptl-1 survived better under acute heat shock (37 degrees Celsius for 2.5 hours), showed fewer axonal blebs, and maintained better motility. They also survived treatment with antimycin A, a mitochondrial complex III inhibitor that would otherwise be lethal.
Under standard laboratory conditions (20 degrees Celsius), however, the ptl-1 knockout worms had shorter lifespans than wild-type, a finding the authors attribute to elevated reactive oxygen species (ROS) production from the hyperfused mitochondrial network. Treatment with the antioxidant N-acetylcysteine rescued the lifespan defect at 20 degrees. Under mild heat stress (25 degrees), the knockout worms actually lived longer, suggesting the trade-off between ROS production and stress resilience is context-dependent.
Implications for Neurodegeneration
The finding reframes how researchers think about Tau’s role in disease. Most prior work has focused on how pathological, aggregated Tau disrupts mitochondrial dynamics, by impairing mitophagy, blocking fission through Drp1 interactions, or causing mitochondrial transport defects. This study shows that wild-type Tau has a normal, physiological role in restraining fusion. Losing that function, whether through Tau aggregation (which sequesters the protein away from its normal duties) or through genetic knockout, may itself contribute to the mitochondrial dysregulation seen in tauopathy.
“The loss of Tau’s normal function and the gain of toxic function from aggregates are not mutually exclusive,” Palikaras said. “Both may contribute to the mitochondrial pathology in Alzheimer’s disease.”
The therapeutic implication is that modulating mitofusin activity could recapitulate the benefits of Tau reduction, enhanced stress resistance, without completely removing Tau, which remains essential for microtubule stabilization throughout the nervous system.
Limitations
The study uses model organisms, C. elegans and mice, not human neurons or patient tissue. While the evolutionary conservation is strong, direct human validation is absent. The analysis focused on whole-brain mitochondria and primary cortical neurons in mice and on GABAergic neurons in worms; regional specificity within the brain was not deeply explored. The study also used only wild-type Tau knockout models, not disease-relevant Tau mutants (such as P301L or R406W seen in frontotemporal dementia), so it remains unclear whether the physiological fusion-restraining function is retained or lost in mutant Tau. The molecular details of how Tau physically restrains mitofusin activity, whether through direct binding or indirect signaling, also remain to be established.
Source: Tsakiri, E., Campos-Marques, C., Ploumi, C. et al. “Tau protein as a regulator of mitochondrial function and dynamics.” Proceedings of the National Academy of Sciences 123(27), e2521642123 (2026). DOI: 10.1073/pnas.2521642123